Curat Global LLC Sells 2,360 Shares of Johnson & Johnson $JNJ

Curat Global LLC cut its stake in Johnson & Johnson (NYSE:JNJ) by 34.5% in the 3rd quarter, Holdings Channel.com reports. The firm owned 4,475 shares of the company’s stock after selling 2,360 shares during the quarter. Johnson & Johnson makes up about 0.8% of Curat Global LLC’s portfolio, making the stock its 29th largest position. Curat Global LLC’s holdings in Johnson & Johnson were worth $824,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the stock. SOA Wealth Advisors LLC. lifted its holdings in shares of Johnson & Johnson by 0.7% in the third quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company’s stock worth $1,371,000 after buying an additional 53 shares in the last quarter. Ethos Financial Group LLC increased its holdings in Johnson & Johnson by 0.6% during the 3rd quarter. Ethos Financial Group LLC now owns 9,110 shares of the company’s stock worth $1,689,000 after acquiring an additional 53 shares during the period. Heritage Oak Wealth Advisors LLC lifted its stake in Johnson & Johnson by 3.5% in the 3rd quarter. Heritage Oak Wealth Advisors LLC now owns 1,639 shares of the company’s stock worth $304,000 after purchasing an additional 55 shares in the last quarter. Lifestyle Asset Management Inc. boosted its holdings in Johnson & Johnson by 3.4% in the 3rd quarter. Lifestyle Asset Management Inc. now owns 1,683 shares of the company’s stock valued at $312,000 after purchasing an additional 56 shares during the period. Finally, Wynn Capital LLC grew its position in shares of Johnson & Johnson by 0.4% during the 3rd quarter. Wynn Capital LLC now owns 15,930 shares of the company’s stock valued at $2,954,000 after purchasing an additional 57 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $218.81 on Tuesday. The firm has a market cap of $527.18 billion, a P/E ratio of 21.12, a P/E/G ratio of 2.25 and a beta of 0.34. The firm’s fifty day moving average is $206.43 and its 200 day moving average is $187.62. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $220.11. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.4%. Johnson & Johnson’s payout ratio is currently 50.19%.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analysts are becoming more constructive on JNJ heading into 2026, citing improving fundamentals and durable cash flow that support the dividend and valuation. Analysts Turn More Constructive on Johnson & Johnson
• Positive Sentiment: Zacks highlights J&J alongside other large names and notes strong pharma and MedTech momentum, which could underpin revenue growth and investor confidence heading into earnings. Zacks Investment Ideas feature highlights
• Positive Sentiment: JNJ continues to be recommended as a dividend holding in retail investor lists, reinforcing demand from income‑oriented investors given its yield and payout consistency. 3 Dividend Stocks to Own
• Neutral Sentiment: Multiple pre‑earnings analyst pieces (TipRanks, Zacks) note JNJ’s Q4 revenue expectations (~$24.16B, roughly +7% YoY) and discuss positioning strategies for investors who want exposure but want to limit risk ahead of the print. Is JNJ Stock a Buy Ahead of Q4?
• Neutral Sentiment: Zacks’ Q&A on buy/hold/sell frames JNJ as a mixed case: strong product momentum but headline risk into the report — useful context but not a direct catalyst. Should You Buy, Sell or Hold J&J Ahead of Q4?
• Negative Sentiment: Seeking Alpha warns J&J is tempering expectations after a sizable 2025 downgrade, highlighting margin and growth pressures that could weigh on sentiment if management echoes lowered guidance. Tempering Expectations After A Massive 2025
• Negative Sentiment: Zacks and other previews call out near‑term headwinds: Stelara biosimilar competition and China market pressures that could blunt top‑line growth and weigh on the print. Buy/Sell/Hold Preview
• Negative Sentiment: Bank of America maintained a Hold rating, signaling limited near‑term upside in analyst coverage and possibly contributing to cautious positioning. Bank of America Sticks to Hold

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Cowen reissued a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Royal Bank Of Canada set a $240.00 price target on Johnson & Johnson in a report on Wednesday, December 17th. Bank of America boosted their price objective on Johnson & Johnson from $204.00 to $220.00 and gave the stock a “neutral” rating in a report on Monday, December 15th. Scotiabank initiated coverage on shares of Johnson & Johnson in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 target price on the stock. Finally, Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Four analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $213.33.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.